靶向逆转P-糖蛋白介导肿瘤多药耐药的研究进展
作者：黄思超;徐俊;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2009,24(05):-551-554
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：P-糖蛋白;多药耐药;靶向;逆转
Key words：
基金项目：国家自然科学基金资助项目(批准号:30572209)
中文摘要
P-糖蛋白(P-gp)的过度表达与肿瘤细胞的多药耐药性(MDR)密切相关,被认为是导致肿瘤化疗失败的主要原因之一。综述近年在P-gp的结构与功能、影响mdr-1表达调控因素、逆转P-gp介导MDR的潜在靶点等方面的研究进展。
参考文献
[1]Pusztai L,Wagner P,Ibrahim N,et al.Phase II study of Tariqui-dar,a selective P-glycoprotein inhibitor,in patients with chem-otherapy-resistant,advanced breast carcinoma[J].Cancer,2005,104(4):682-691.
[2]Loo TW,Bartlett MC,Clarke DM.Substrate-induced conforma-tional changes in the transmembrane segments of human P-gly-coprotein-direct evidence for the substrate-induced fit mecha-nism for drug binding[J].J Biol Chem,2003,278(16):13603-13606.
[3]Berridge G,Walker JA,Callaghan R,et al.The nucleotide bind-ing domains of P-glycoprotein functional symmetry in the isola-ted domain demonstrated by N-ethylmaleimide abeling[J].EurJ Biochem,2003,270(7):1483-1492.
[4]Procko E,Ferrin-O’Connell I,Ng SL,et al.Distinct structuraland functional properties of the ATPase sites in an asymmetricABC transporter[J].Mol Cell,2006,24(1):51-62.
[5]Martin C,Berridge G,Higgins CF,et al.Communication betweenmultiple drug binding sites on P-glycoprotein[J].Mol Pharma-col,2000,58(3):624-632.
[6]Pleban K,Ecker GF.Inhibitors of P-glycoprotein-lead identi-fication and optimization[J].Mini Rev Med Chem,2005,5(2):153-163.
[7]Lawson J,O’Mara ML,Kerr ID.Structure-based interpretationof the mutagenesis database for the nucleotide binding domains ofP-glycoprotein[J].BBA-Biomemberanes,2008,1778(2):376-391.
[8]Loo TW,Bartlett MC,Clarke DM.Nucleotide binding,ATP hy-drolysis,and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the trans-membrane segments[J].Biochemistry,2007,46(32):9328-9336.
[9]Rothnie A,Storm J,McMahon R,et al.The coupling mechanism ofP-glycoprotein involves residue L339 in the sixth membrane span-ning segment[J].FEBS Lett,2005,579(18):3984-3990.
[10]Dey S,Hafkemeyer P,Pastan I,et al.A single amino acid residuecontributes to distinct mechanisms of inhibition of the human mul-tidrug transporter by stereoisomers of the dopamine receptor antag-onist flupentixol[J].Biochemistry,1999,38(20):6630-6639.
[11]Bentires-Alj M,Barbu V,Fillet M,et al.NF-kappa B tran-scription factor induces drug resistance through MDR1 expressionin cancer cells[J].Oncogene,2003,22(1):90-97.
[12]Shibahara K,Uchiumi T,Fukuda T,et al.Targeted disruption ofone allele of the Y-box binding protein-1(YB-1)gene inmouse embryonic stem cells and increased sensitivity to cisplatinand mitomycin C[J].Cancer Sci,2004,95(4):348-353.
[13]Britz-Cunningham SH,Adelstein SJ.Molecular targeting withradionuclides:State of the science[J].J Nucl Med,2003,44(12):1945-1961.
[14]Zhu H,Chen XP,Luo SF,et al.Involvement of hypoxia induc-ible factor-1 alpha in multidrug resistance induced by hypoxia inHepG2 cells[J].J Exp Clin Cancer Res,2005,24(4):565-574.
[15]Oka M,Kounoura K,Naraski F,et al.P-glycoprotein is posi-tively correlated with p53 protein accumulation in human colorec-tal cancers[J].Jpn J Cancer Res,1997,88(8):738-742.
[16]David GL,Yegnasubramanian S,KumarA,et al.MDR1 promoterhypermethylation in MCF-7 human breast cancer cells:changesin chromatin structure induced by treatment with 5-aza-cyti-dine[J].Cancer Biol Ther,2004,3(6):540-548.
[17]Tabe Y,Konopleva M,Contractor R,et al.Up-regulation ofMDR1 and induction of doxorubicin resistance by histone deacety-lase inhibitor depsipeptide(FK228)and ATRAin acute promye-locytic leukemia cells[J].Blood,2006,107(4):1546-1554.
[18]Kanzaki A,Takebayashi Y,Ren XQ,et al.Overcoming multidrugdrug resistance in P-glycoprotein/MDR1-overexpressing celllines by ecteinascidin743[J].Mol Cancer Ther,2002,1(14):1327-1334.
[19]Kimchi-Sarfaty C,Oh JM,Kim IW,et al.A silent polymor-phism in the MDR1 gene changes substrate specificity[J].Sci,2007,315:525-528.
【关闭】
